Solutia Reports Third Quarter 20...(--- --- --- ...)

Date:10/26/2009

--- --- --- --- Income (Loss) from Continuing Operations attributable to Solutia 49 1,250 (1) 1,249 Plus: Events affecting comparability, pre-tax: Reorganization items - (1,433) - (1,433) Interest expense items 8 - 1 1 Other items (see below) 17 (2) 65 63 Events affecting comparability, income tax impact (3) 202 (15) 187 --- --- --- --- Income from Continuing Operations attributable to Solutia before events affecting comparability $71 $17 $50 $67 --- --- --- --- Summary of Events Affecting Comparability In 2009, (Gains) and Charges affecting comparability, pre-tax other items including interest are as follows: Three Three Three Nine Months Months Months Months Ended Ended Ended Ended March 31, June 30, Sept 30, Sept 30, 2009 2009 2009 2009 (dollars in millions) ---- ---- ---- ---- Gain related to the reduction in the 2008 $(23) $- $- $(23) annual incentive plan Severance and retraining costs related to the general corporate 17 5 4 26 restructuring Charges related to the closure of the
'/>"/>

SOURCE Solutia Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
Related biology technology :

1. Solutia Reports First Quarter 2009 Results
2. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
3. Hanger Orthopedic Group, Inc. Reports an Increase of 30.4% in Earnings Per Share, to $0.30, for the Third Quarter 2009 and Raises Its 2009 Guidance
4. NuVasive Reports Third Quarter 2009 Financial Results
5. Raptor Pharmaceutical Reports Positive Interim Phase 2a Clinical Data in Non-Alcoholic Steatohepatitis (NASH)
6. Fibrocell Science, Inc. Reports Outcome of FDA Advisory Committee Meeting on Azfibrocel-T for Wrinkles
7. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
8. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
9. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
10. Neogen Reports 18% Increase in Net Income, 12% Increase in Revenues
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009